<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353454</url>
  </required_header>
  <id_info>
    <org_study_id>SHP625-306</org_study_id>
    <secondary_id>2017-003138-99</secondary_id>
    <nct_id>NCT03353454</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)</brief_title>
  <official_title>Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment (maralixibat) is
      safe and effective in pediatric participants with Progressive Familial Intrahepatic
      Cholestasis (PFIC).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was withdrawn due to change of ownership of the study drug maralixibat. Future
    studies of maralixibat will be posted by Mirum Pharmaceuticals.
  </why_stopped>
  <start_date type="Anticipated">October 25, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response as Measured by the Observer Itch Reported Outcome (ItchRO[Obs])</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Compare the percentage of participants on active treatment versus (vs.) placebo who meet response criteria which is defined as improvement in before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) severity decrease from baseline demonstrated on at least 2 of the last 3 study visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response as Measured by the Observer Itch Reported Outcome (ItchRO[Obs]) and Serum Bile Acids (sBA)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Compare the percentage of participants on active treatment versus (vs.) placebo who meet response criteria which is defined as improvement in average before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) severity decrease from baseline and normalization or reduction from baseline sBA demonstrated on at least 2 of the last 3 study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization or Reduction From Baseline in Serum Bile Acids (sBA)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Compare the percentage of participants on active treatment vs. placebo with normalization or significant reduction from baseline in sBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Daily Average Itch Reported Outcome (ItchRO[Obs]) Score</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Change over time in daily average ItchRO scores will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Before Midday (AM) Itch Reported Outcome (ItchRO[Obs]) Score</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Change over time in AM ItchRO scores will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in After Midday (PM) Itch Reported Outcome (ItchRO[Obs]) Score</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Change over time in PM ItchRO scores will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance of Pruritus as Measured by Observer Itch Reported Outcome (ItchRO[Obs])</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Compare the percentage of participants on active treatment vs. placebo of participants who experience disappearance of pruritus as measured by ItchRO(Obs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Height</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Number of participants on active treatment vs. placebo with a height z-score change from baseline &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Weight</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Number of participants on active treatment vs. placebo with a weight z-score change from baseline &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nutritional Status as Measured by Mid-arm Circumference</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change in nutritional status as measured by mid-arm circumference in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nutritional Status as Measured by Triceps Skin Fold</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change in nutritional status as measured by triceps skin fold in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician Scratch Scale (CSS)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change in Clinician Scratch Scale score in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Measured by Pediatric Quality of Life Inventory (PedsQL)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change from baseline of PedsQL in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Sleep as Measured by Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Compare the change from baseline of CSHQ in participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization or Meaningful Reduction From Baseline of Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Number of participants whose ALT normalizes on treatment or has decreased &gt;=50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization or Meaningful Decrease From Baseline of Total Bilirubin</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Number of participants whose total bilirubin normalizes on treatment or has decreased &gt;=50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarkers of Bile Acid Synthesis</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change from baseline in biomarkers of bile acid synthesis (serum 7 alpha-hydroxy-4-cholesten-3-one [C4]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of SHP625</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Adverse events, changes in vital signs, laboratory, and other safety parameters will be compared between participants on active treatment vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Maralixibat Over Time</measure>
    <time_frame>Baseline, Week 6, 10, 14, 18, 22 and 26</time_frame>
    <description>Systemic concentrations of maralixibat in plasma will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis (PFIC)</condition>
  <arm_group>
    <arm_group_label>Maralixibat (SHP625)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.</description>
    <arm_group_label>Maralixibat (SHP625)</arm_group_label>
    <other_name>SHP625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to maralixibat orally twice daily for 26 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Informed consent and assent (as applicable for participants less than or equal to (&lt;=)
             18 years per Institutional Review Board/Ethics Committee (IRB)/Ethics Committee (EC)
             as appropriate.

          -  Male or female participants between the ages of 12 months and 18 years inclusive
             (primary cohort) or birth to 18 years inclusive (exploratory cohort) at time of
             consent, with a body weight greater than or equal to (&gt;=) 5 kilogram (kg).

          -  Cholestasis as manifested by total sBA greater than (&gt;) 3*upper limit of normal (ULN)

          -  An average AM ItchRO(Obs) score &gt;= 1.5 during the 4 weeks leading to the baseline
             visit

          -  Diagnosis of PFIC based on:

             a. Primary cohort: i. Participants with 2 documented mutant alleles in ABCB11 (PFIC2);
             participants without bile salt export pump (BSEP) function (biallelic truncating
             mutations in ABCB11) will not be enrolled into the primary cohort. b. Exploratory
             cohort: i. Participants with PFIC1/3/4 or PFIC2 with biallelic truncating
             mutationsiii.Infants from birth to &lt;12 months of age with PFIC ii. Participants with
             PFIC after internal or external (eg, PEBD) biliary diversion surgery with
             unsatisfactory pruritus control or where biliary diversion was reversed.

        Key Exclusion Criteria:

          -  Chronic diarrhea requiring intravenous fluid or nutritional intervention for the
             diarrhea and/or its sequelae.

          -  History of surgical disruption of the enterohepatic circulation (applies to primary
             cohort only).

          -  Liver transplant

          -  Decompensated cirrhosis (international normalized ratio [INR] &gt;1.5, albumin &lt;30 gram
             per liter [g/L], history or presence of clinically significant ascites, variceal
             hemorrhage, and/or encephalopathy).

          -  ALT &gt;15*ULN at screening.

          -  History or presence of other liver disease.

          -  History or presence of any other disease or condition known to interfere with the
             absorption, distribution, metabolism or excretion of drugs, including bile salt
             metabolism in the intestine (example [eg], inflammatory bowel disease), per
             investigator discretion.

          -  Liver mass on imaging

          -  Known diagnosis of human immunodeficiency virus (HIV) infection.

          -  Any prior cancer diagnosis except for in situ carcinoma or cancers treated within 5
             years of the screening visit (Visit 0) with no evidence of recurrence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Mirum</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholestasis</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

